1,916 material Form 8-K filings that 1,609 companies we cover made with the SEC in July 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
NextPlat's indirect subsidiary Progressive Care, LLC agreed on July 14, 2026 to acquire 100% of Scott's Pharmacy, LLC, a community pharmacy in Molino, Florida, for $1.5 million in cash, subject to an inventory adjustment. The filing says the pharmacy generated about $5.6 million in sales in 2025, and the deal is expected to expand NextPlat's PharmcoRx retail and contracted-services footprint in the panhandle region, though closing is not yet complete.
Purchase price is $1,500,000 in cash, with a $50,000 initial escrow deposit credited at closing and $50,000 held in escrow for indemnification for 18 months after closing.
Closing is targeted by September 30, 2026, with a one-time extension to October 31, 2026, available upon notice and an additional $50,000 deposit.
The Company has a 30-day due diligence period and must negotiate a lease for the premises; failure to do so allows termination without penalty.
Per the press release, the pharmacy had approximately $5.6 million in 2025 sales and retail margins of about 19%, and NextPlat's 2025 annual revenue was $54.3 million.
SBA Communications agreed on July 14, 2026 to sell $3.5 billion of senior notes in a registered public offering through four underwriters. The company plans to use the net proceeds to repay in full its senior secured term loan and its outstanding revolving credit facility borrowings. The filing does not state the effect on earnings or leverage.
Notes: $1.35 billion of 4.875% due 2030, $1.35 billion of 5.150% due 2031, and $800 million of 5.450% due 2033
Underwriting agreement dated July 14, 2026, with Morgan Stanley, Barclays, Wells Fargo Securities and Goldman Sachs as representatives
Proceeds to repay the term loan maturing January 25, 2031 and revolver borrowings maturing January 25, 2029
Lamb Weston amended its 2026 Inducement Stock Plan on July 13, 2026, reducing the number of common shares authorized for issuance under the plan from 2,000,000 to 1,538,000. The plan is used to grant equity to new hires and returning employees, so the change limits the shares available for those grants.
Amendment adopted July 13, 2026 by the Compensation and Human Capital Committee
Authorized shares reduced from 2,000,000 to 1,538,000
Plan covers individuals not previously employed by the company or returning after a bona fide period of non-employment
The Hanover Insurance Group said CEO John C. Roche will retire as president, CEO and board member effective December 31, 2026. Chief Operating Officer Richard W. Lavey has been named CEO-elect and is expected to succeed Roche as CEO at that time, with a board seat from January 1, 2027. The filing reports no financial results, but it changes the company's top executive role.
John C. Roche, 62, retires as president, CEO and board member effective December 31, 2026, and stays as an advisor through January 8, 2027.
Richard W. Lavey, 59, has been Executive Vice President and Chief Operating Officer since March 2025 and is named CEO-elect.
The Board intends to elect Lavey to the Board effective January 1, 2027.
The company's earnings call is scheduled for July 29, 2026, and its investor day for September 17, 2026.
Yorkville Acquisition Corp., a blank-check company, issued an amended and restated convertible promissory note for $500,000 to its sponsor on May 4, 2026, after the sponsor advanced an additional $250,000 for working capital. The note bears no interest and is payable at the earlier of the company's initial business combination or the effective date of its winding up; the sponsor may convert it into units at $10.00 each upon a business combination. For shareholders, this increases the company's obligations to the sponsor and could add up to 50,000 new units, which would dilute existing holders if converted.
Amended and restated note dated May 4, 2026 totals $500,000, replacing a $250,000 note issued February 11, 2026
Sponsor advanced an additional $250,000 on May 4, 2026 for working capital
Note is non-interest bearing and convertible at $10.00 per unit into New Units upon a business combination, capped at 50,000 units
Each New Unit includes one Class A ordinary share and one-third of a warrant exercisable at $11.50
Samos Energy Acquisition Corporation closed its initial public offering of 23,000,000 units at $10.00 per unit on July 13, 2026, for gross proceeds of $230 million, including the full exercise of the underwriters' overallotment option. The company also sold 6,000,000 private placement warrants for $6 million and appointed three new directors, and it must complete a business combination within 24 months of the IPO closing or return public funds.
23,000,000 units sold at $10.00 each, for gross proceeds of $230 million, including 3,000,000 overallotment units (Exhibit 99.2)
Private sale of 6,000,000 warrants at $1.00 each on July 13, 2026, for gross proceeds of $6 million, to the Sponsor and Cantor
Trent Kososki, Joseph McMonigle and Khodor Mattar appointed directors on July 10, 2026; Mattar chairs the audit committee and McMonigle chairs the compensation committee
The 8-K says $200 million was deposited in trust, while Exhibit 99.2 says $230 million was placed in trust; the filing does not reconcile the two figures
Aldeyra received minutes from a June 10, 2026 Type A meeting with the FDA about potential resubmission of the New Drug Application for reproxalap, a treatment for dry eye disease. The company has asked the FDA for a clarification of the minutes and plans to request a Type D meeting to discuss resubmission, which is expected by the end of the third quarter of 2026.
Type A meeting with the FDA held June 10, 2026; minutes received July 14, 2026
Clarification of the minutes requested from the FDA on July 15, 2026
Type D meeting on NDA resubmission expected by end of third quarter 2026
Deere Funding Canada Corporation, an indirect wholly owned subsidiary, agreed on July 10, 2026 to sell $300 million of 4.850% notes due July 15, 2031, fully and unconditionally guaranteed by Deere & Company on a senior unsecured basis. The filing is a routine debt issuance under an existing 2020 indenture and registration statement, and it does not report any change to Deere's financial results or guidance.
Issuer agreed to sell $300,000,000 aggregate principal amount of 4.850% Notes due July 15, 2031, on July 10, 2026
Interest payable January 15 and July 15 each year, beginning January 15, 2027
Notes rank equally with Deere's other senior unsecured debt; underwriters include Barclays Capital, Deutsche Bank Securities and RBC Capital Markets
Issued under an indenture dated June 15, 2020 with The Bank of New York Mellon; final prospectus supplement filed July 13, 2026
American Airlines Group elected John W. Dietrich to its Board of Directors on July 15, 2026, and he will serve on the Audit and Finance Committees. Dietrich most recently was Executive Vice President and CFO of FedEx from 2023 to 2026, and previously spent more than two decades at Atlas Air Worldwide. The filing describes a board addition with finance and governance experience, and it reports no financial results or changes to company guidance.
Dietrich was elected to the board on July 15, 2026, and will serve on the Audit Committee and Finance Committee.
He was Executive Vice President and CFO of FedEx Corporation from 2023 to 2026.
He spent more than two decades at Atlas Air Worldwide, including as President and CEO.
He will receive director compensation on the same basis as other non-employee directors.
Gladstone Land's board authorized repurchases of up to $20 million of its 6.00% Series B preferred stock and up to $35 million of its 6.00% Series C preferred stock, running through July 14, 2027. The company is not obligated to buy any particular amount, and the program can be suspended or discontinued at any time, so the effect on preferred holders and common shareholders will depend on how much is actually bought.
Series B authorization: up to $20,000,000 (Nasdaq: LANDO)
Series C authorization: up to $35,000,000 (Nasdaq: LANDP)
Program expires July 14, 2027; repurchases may be made through open market or privately negotiated transactions
Nomadar Corp. said it completed the acquisition of approximately 290,000 square meters of land in El Puerto de Santa María, Cádiz, Spain, for the planned JP Financial Arena. The closing follows binding agreements signed in April and May 2026 and gives the company effective control over the entire land asset. The filing does not disclose a purchase price, and it contains no financial results or guidance.
Land totals about 290,000 square meters, including about 130,000 square meters from an April 2026 binding offer and about 161,000 additional square meters from a May 2026 binding agreement.
Closing was announced July 15, 2026, and Nomadar says it now has effective control over the entire strategic land asset.
The filing does not state the purchase price or how the acquisition will be funded.
The Hartford Insurance Group named Randy Larsen, former CEO of AssuredPartners, as a director effective September 1, 2026, and placed him on the Finance, Investment and Risk Management Committee and the Nominating and Corporate Governance Committee. The change adds a director with insurance brokerage leadership experience and carries modest director pay, so it is a routine board addition rather than a change in company operations or financial results.
Randy Larsen's board service begins September 1, 2026, and he joins the Finance, Investment and Risk Management Committee and the Nominating and Corporate Governance Committee.
Larsen was CEO of AssuredPartners from 2023 until its acquisition by Gallagher in 2025, after 13 years with the firm.
For the remainder of the 2026-2027 board service year, he will receive a pro rata cash retainer of $82,700 and restricted stock units valued at $136,600.
The board determined that Larsen meets New York Stock Exchange independence requirements.
RxSight's board appointed Aziz Mottiwala as President and Chief Executive Officer on July 13, 2026, effective July 20, 2026, replacing Ron Kurtz, M.D., who has led the company since 2016. Kurtz moves to Chief Medical Officer and resigns from the board, and Mottiwala joins the board in his place. The company said it is not updating its previously communicated financial guidance.
Mottiwala, 48, was Chief Commercial Officer of Tarsus Pharmaceuticals from August 2020 to July 2026.
Mottiwala's pay includes a $750,000 base salary, a 2026 cash bonus of $337,500, and equity awards with a grant-date value of $14,000,000.
Kurtz keeps a $740,000 base salary and can earn retention bonuses of $370,000 on each of four dates from January 1, 2027 through July 1, 2028, if he remains employed.
The company is not updating its previously communicated financial guidance in connection with the announcement.
On July 12, 2026, First Hawaiian, Inc. signed a merger agreement with TriCo Bancshares, under which TriCo will merge into a First Hawaiian subsidiary and then into First Hawaiian, followed by a bank merger of Tri Counties Bank into First Hawaiian Bank. TriCo shareholders will receive 2.095 First Hawaiian shares for each TriCo share, so the deal would dilute existing First Hawaiian shareholders and depends on shareholder, regulatory and registration approvals.
Exchange ratio: each TriCo common share converts into 2.095 First Hawaiian common shares, with cash paid in lieu of fractional shares
Termination fee of $80 million payable by either party in certain circumstances
Four TriCo directors will join the First Hawaiian board at the effective time
Closing requires stockholder and shareholder approvals, Federal Reserve, FDIC and state regulatory approvals, and effectiveness of a Form S-4 registration statement
Lakewood-Amedex Biotherapeutics made a corporate investor presentation available on July 15, 2026, describing its Bisphosphocin compound platform and its lead program, Nu-3, a topical antimicrobial gel for infected diabetic foot ulcers. The filing contains no financial results, guidance, or new financing, and the deck states that Phase 2a clinical trial milestones run from 3Q26 through 4Q26/1Q27 for top-line results.
Investor deck dated July 15, 2026, furnished as Exhibit 99.1 under Regulation FD and not deemed filed under the Exchange Act.
Deck lists Phase 2a trial milestones: clinical trial commences and first patient first visit in 3Q26; clinical trial complete in 4Q26; top-line results expected 4Q26/1Q27.
Intellectual property: 71 issued and 30 pending patents, with key filings providing protection through 2038 and recent applications through 2044.
RLI Corp.'s Board appointed James H. Bradshaw as a director effective July 15, 2026, and named him to the Audit and Finance & Risk Committees. The Board determined he is independent under New York Stock Exchange rules, and he will stand for election at the next annual shareholders' meeting. The filing describes this as a board addition and reports no financial results.
James H. Bradshaw appointed to the Board effective July 15, 2026
Board determined Mr. Bradshaw is independent under NYSE rules
Appointed to the Audit and Finance & Risk Committees; term expires at the May 2027 shareholders' meeting
Bradshaw is Chairman of Gallagher Re North America, a role he assumed in 2024
Martin Marietta entered a $1.5 billion three-year senior unsecured term loan on July 15, 2026, and amended its $800 million revolving credit facility on July 10, 2026. Both are tied to its previously announced acquisition of Lhoist North America, with the term loan's proceeds usable to pay part of the cash consideration. The filing sets a maximum leverage ratio that steps down after the deal closes, which shows the debt load the company will carry.
Term Facility: $1,500,000,000 three-year senior unsecured term loan with JPMorgan Chase Bank, N.A. as administrative agent, available subject to the Lhoist North America acquisition closing
Revolving facility amendment dated July 10, 2026 sets maximum leverage ratio of 4.75:1.00 for the first three fiscal quarters after closing, 4.25:1.00 for the next three, and 3.75:1.00 thereafter
Commitment fee on undrawn term loan commitments begins October 25, 2026
Prestige Brands, a wholly owned subsidiary of Prestige Consumer Healthcare, issued $400.0 million of 6.250% senior notes due July 15, 2034, under an indenture dated July 15, 2026. The notes are unsecured and guaranteed by the parent company, adding $400 million of long-term debt that shareholders will carry alongside existing obligations.
Principal amount: $400.0 million of 6.250% senior notes due July 15, 2034
Interest payable January 15 and July 15 each year, starting January 15, 2027
Parent company and certain domestic subsidiaries guarantee the notes on an unsecured senior basis
Change of Control triggers an offer to repurchase at 101% of principal; notes may be redeemed from July 15, 2029
The trustee reported a July 1, 2026 distribution of $1.025625 per $25 certificate, all of it interest, with no principal and no unpaid interest. The filing is a routine trustee notice on a trust holding $40,170,000 of Aon Capital A 8.205% Capital Securities due January 1, 2027, and it contains no change to the underlying securities or their issuer, Aon plc.
Distribution date: July 1, 2026; class A interest of $1.025625 per $25 certificate, principal of $0.000000
Aggregate interest due and not paid as of the distribution date: $0.000000
1,606,800 certificates outstanding, representing $40,170,000 in certificate principal balance
Underlying Term Assets: $40,170,000 of Aon Capital A 8.205% Capital Securities due January 1, 2027; no fees paid to the trustee from the Term Assets proceeds
Tennessee Valley Authority entered into a Third Amended and Restated $1 billion July Maturity Credit Agreement on July 10, 2026, replacing its March 2022 facility. The agreement allows TVA to borrow or obtain letters of credit of up to $1 billion and expires on July 10, 2031, unless extended, so it adds a revolving source of liquidity with a long maturity for shareholders to note.
Facility size: up to $1 billion in loans or letters of credit
Agreement dated July 10, 2026; expires July 10, 2031 unless extended
Administrative Agent: Toronto Dominion (Texas) LLC; Lead Arranger and Bookrunner: TD Securities (USA) LLC
Interest rate and unused facility fee vary with the rating of TVA's senior unsecured long-term non-credit enhanced debt
Axsome Therapeutics said the FDA accepted its New Drug Application for AXS-12 (reboxetine) for the treatment of cataplexy in narcolepsy. The FDA set a PDUFA target action date of May 1, 2027, and does not currently plan an advisory committee meeting. AXS-12 is not approved by the FDA, and the filing contains no financial results.
FDA accepted the New Drug Application for AXS-12 (reboxetine) for cataplexy in narcolepsy for filing
PDUFA target action date set for May 1, 2027
FDA does not currently plan to hold an advisory committee meeting
AXS-12 has FDA Orphan Drug Designation for the treatment of narcolepsy
Pediatrix Medical Group said in a July 15, 2026 update on its second quarter that its payor mix stayed stable and in line with recent trends and internal expectations, and it has not seen material changes in other net revenue trends. The company reaffirmed its full year 2026 Adjusted EBITDA outlook of $280 million to $300 million, and it did not report second quarter financial results in this filing. Full results are due in a release on August 4, 2026.
Full year 2026 Adjusted EBITDA outlook reaffirmed at $280 million to $300 million
Second quarter payor mix stable and unchanged relative to recent historical trends and internal expectations
Company says it has not experienced the unfavorable payor mix shifts reported elsewhere in the healthcare sector
Investor conference call and detailed results release scheduled for August 4, 2026, at 9:00 a.m. ET
Smith & Wesson Brands held an investor day at its Tennessee headquarters on July 15, 2026, and furnished a slide presentation as Exhibit 99.1. The slides cite FY26 net revenue of $523.8 million, a net income increase of more than 10% year over year, and 1.1 million firearms shipped, though the filing itself contains no new financial results or guidance.
FY26 net revenue of $523.8 million, with net revenue growth of more than 10% year over year
Net income increased 37.7% year over year, per the presentation
Firearms shipped totaled 1.1 million, a 12.7% increase year over year
New products generated 38.1% of FY26 revenue; suppressor revenue grew 95.6% in the first six months of calendar 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.